A phase 1b, dose-finding study of ruxolitinib plus panobinostat in patients with myelofibrosis.
Florian Heidel
Consultant or Advisory Role - Novartis
Honoraria - Novartis
Research Funding - Novartis
Vincent Ribrag
No relevant relationships to disclose
Alessandro M. Vannucchi
Consultant or Advisory Role - Novartis
Jean-Jacques Kiladjian
Consultant or Advisory Role - Novartis; Sanofi
Research Funding - Novartis
Francesco Passamonti
Consultant or Advisory Role - Novartis
Amjad Hayat
No relevant relationships to disclose
Eibhlin Conneally
Honoraria - Novartis
Other Remuneration - Novartis
Thomas Kindler
Consultant or Advisory Role - Novartis
Bruno Martino
No relevant relationships to disclose
Daniel B Lipka
Consultant or Advisory Role - Novartis
Honoraria - Novartis
Research Funding - Novartis
Suddhasatta Acharyya
Employment or Leadership Position - Novartis
Florence Binlich
Employment or Leadership Position - Novartis
Tracy Liu
Employment or Leadership Position - Novartis
Song Mu
Employment or Leadership Position - Novartis
Stock Ownership - Novartis
Claire N. Harrison
Honoraria - Gilead Sciences; Novartis; Sanofi ; Shire
Research Funding - Novartis